Renal Cell Carcinoma
INACTIVE --- Second-line therapy in metastatic ccRCC

Charlie (72 years old)

Charlie is a 72-year-old retired army officer. He was diagnosed with metastatic ccRCC 2 years ago with histologically confirmed lung and adrenal gland metastasis.

 

Assessment summary:

  • ECOG PS: 0
  • KPS: 100%
  • No relevant past medical history
  • IMDC: intermediate risk
  • 1st-line therapy with pazopanib (800 mg/day) for 4 months, partial remission
  • Therapy break for 6 months due to elevated liver enzymes
    • Restaging at end of 6 month therapy break showed stable disease
    • Liver enzymes declined after 6 month therapy break
  • Rechallenge with pazopanib 400 mg/day for 2 months
    • Treatment discontinued due to elevated liver enzymes (WHO grade 3)
    • Restaging: progression of lung metastasis on CT

 

Which treatment option would you choose for this patient?